Patents by Inventor Tadahiro Nambu

Tadahiro Nambu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY FOR CANCER TREATMENT
    Publication number: 20220323443
    Abstract: The present disclosure relates to the treatment of cancer using a combination therapy comprising Compound 1 and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof, and a second therapy.
    Type: Application
    Filed: July 17, 2020
    Publication date: October 13, 2022
    Inventors: Akihiro Ohashi, Kenichi Iwai, Tadahiro Nambu, Jie Yu, Kurt Eng, Michael Joseph Kuranda, Kazuho Nishimura, Cong Li
  • Method of predicting effects of CDC7 inhibitor
    Patent number: 11155879
    Abstract: The present invention relates to a method of predicting the likelihood that a patient will respond therapeutically to a pancreatic cancer treatment comprising the administration of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one (Compound 1) and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof, comprising the steps of: STEP (1): determining a KRAS gene mutation status of a sample from a patient, and STEP (2): predicting an increased likelihood that the patient will respond therapeutically to the pancreatic cancer treatment if the patient has the presence of KRAS gene mutation(s), and to methods of treating pancreatic cancer.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: October 26, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Akihiro Ohashi, Kenichi Iwai, Tadahiro Nambu, Ryo Dairiki, Yuko Ishii
  • CANCER TREATMENT METHODS BASED ON TP53 MUTATION STATUS AND HYPERMUTATION STATUS
    Publication number: 20210267980
    Abstract: The present disclosure relates to methods useful for determining whether to treat cancer in a patient, and treating cancer in a patient, by administering a therapeutically effective amount of Compound 1 and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof.
    Type: Application
    Filed: June 18, 2019
    Publication date: September 2, 2021
    Inventors: Akihiro OHASHI, Kenichi IWAI, Tadahiro NAMBU, Kazunori YAMANAKA, Kentaro OTAKE, Huifeng NIU, Hyunjin SHIN, Erik Michael KOENIG
  • METHOD OF PREDICTING EFFECTS OF CDC7 INHIBITOR
    Publication number: 20200010904
    Abstract: The present invention relates to a method of predicting the likelihood that a patient will respond therapeutically to a pancreatic cancer treatment comprising the administration of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one (Compound 1) and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof, comprising the steps of: STEP (1): determining a KRAS gene mutation status of a sample from a patient, and STEP (2): predicting an increased likelihood that the patient will respond therapeutically to the pancreatic cancer treatment if the patient has the presence of KRAS gene mutation(s), and to methods of treating pancreatic cancer.
    Type: Application
    Filed: March 1, 2017
    Publication date: January 9, 2020
    Inventors: Akihiro Ohashi, Kenichi Iwai, Tadahiro Nambu, Ryo Dairiki, Yuko Ishil